Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2018 Aug 25;18(1):174.
doi: 10.1186/s12872-018-0911-4.

Risk profiles and pattern of antithrombotic use in patients with non-valvular atrial fibrillation in Thailand: a multicenter study

Rungroj Krittayaphong  1 , Arjbordin Winijkul  2 , Komsing Methavigul  3 , Wattana Wongtheptien  4 , Chaiyasith Wongvipaporn  5 , Treechada Wisaratapong  6 , Rapeephon Kunjara-Na-Ayudhya  7 , Smonporn Boonyaratvej  8 , Chulalak Komoltri  9 , Pontawee Kaewcomdee  2 , Ahthit Yindeengam  2 , Piyamitr Sritara  10 ; COOL-AF Investigators
Collaborators, Affiliations
Multicenter Study

Risk profiles and pattern of antithrombotic use in patients with non-valvular atrial fibrillation in Thailand: a multicenter study

Rungroj Krittayaphong et al. BMC Cardiovasc Disord. .

Abstract

Background: Anticoagulation therapy is a standard treatment for stroke prevention in patients with non-valvular atrial fibrillation (NVAF) that have risk factors for stroke. However, anticoagulant increases the risk of bleeding, especially in Asians. We aimed to investigate the risk profiles and pattern of antithrombotic use in patients with NVAF in Thailand, and to study the reasons for not using warfarin in this patient population.

Methods: A nationwide multicenter registry of patients with NVAF was created that included data from 24 hospitals located across Thailand. Demographic data, atrial fibrillation-related data, comorbid conditions, use of antithrombotic drugs, and reasons for not using warfarin were collected. Data were recorded in a case record form and then transferred into a web-based system.

Results: A total of 3218 patients were included. Average age was 67.3 ± 11.3 years, and 58.2% were male. Average CHADS2, CHA2DS2-VASc, and HAS-BLED score was 1.8 ± 1.3, 3.0 ± 1.7, and 1.5 ± 1.0, respectively. Antiplatelet was used in 26.5% of patients, whereas anticoagulant was used in 75.3%. The main reasons for not using warfarin in those with CHA2DS2-VASc ≥2 included already taking antiplatelet (26.6%), patient preference (23.1%), and using non-vitamin K antagonist oral anticoagulants (NOACs) (22.7%). Anticoagulant was used in 32.3% of CHA2DS2-VASc 0, 56.8% of CHA2DS2-VASc 1, and 81.6% of CHA2DS2-VASc ≥2. The use of NOACs increased from 1.9% in 2014 to 25.6% in 2017.

Conclusions: Anticoagulation therapy was prescribed in 75.3% of patients with NVAF. Among those receiving anticoagulant, 90.9% used warfarin and 9.1% used NOACs. The use of NOACs increased over time.

Keywords: Antithrombotics; Non-valvular atrial fibrillation; Risk profiles; Thailand.

PubMed Disclaimer

Conflict of interest statement

Ethics approval and consent to participate

The study protocol was approved by the institutional review boards of all participating hospitals. Written informed consent was obtained from all included patients prior to participation.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interest.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Figures

Fig. 1
Fig. 1
Use of antithrombotic treatment stratified by CHA2DS2-VASc score (a) and HAS-BLED (b) score. (Abbreviations: AP, antiplatelet; NOAC, non-vitamin K antagonist oral anticoagulant)
See this image and copyright information in PMC

References

    1. Lip GYH, Brechin CM, Lane DA. The global burden of atrial fibrillation and stroke: a systematic review of the epidemiology of atrial fibrillation in regions outside North America and Europe. Chest. 2012;142(6):1489–1498. doi: 10.1378/chest.11-2888. - DOI - PubMed
    1. Tse HF, Wang YJ, Ahmed Ai-Abdullah M, Pizarro-Borromeo AB, Chiang CE, Krittayaphong R, Singh B, Vora A, Wang CX, Zubaid M, et al. Stroke prevention in atrial fibrillation--an Asian stroke perspective. Heart Rhythm. 2013;10(7):1082–1088. doi: 10.1016/j.hrthm.2013.03.017. - DOI - PubMed
    1. Anselmino M, Ferraris F, Cerrato N, Barbero U, Scaglione M, Gaita F. Left persistent superior vena cava and paroxysmal atrial fibrillation: the role of selective radio-frequency transcatheter ablation. J Cardiovasc Med (Hagerstown) 2014;15(8):647–652. doi: 10.2459/JCM.0000000000000144. - DOI - PubMed
    1. Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, Castella M, Diener HC, Heidbuchel H, Hendriks J, et al. 2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016;37(38):2893–2962. doi: 10.1093/eurheartj/ehw210. - DOI - PubMed
    1. Chiang CE, Okumura K, Zhang S, Chao TF, Siu CW, Wei Lim T, Saxena A, Takahashi Y, Siong Teo W. 2017 consensus of the Asia Pacific Heart Rhythm Society on stroke prevention in atrial fibrillation. J Arrhythm. 2017;33(4):345–367. doi: 10.1016/j.joa.2017.05.004. - DOI - PMC - PubMed

Publication types

MeSH terms